IMMX

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Immix Biopharma Inc

NASDAQ | IMMX

7.38

USD

+$0.00

(

+0.00%

)

At Close (As of Dec 11, 2025)

$354.64M

Market Cap

-

P/E Ratio

-0.77

EPS

$7.45

52 Week High

$1.34

52 Week Low

HEALTHCARE

Sector

IMMX Chart

Recent Chart
Price Action

IMMX Technicals

Tags:

IMMX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$115K
Total Revenue $0
Cost Of Revenue $115K
Costof Goods And Services Sold $115K
Operating Income -$23M
Selling General And Administrative $11M
Research And Development $11M
Operating Expenses $23M
Investment Income Net -
Net Interest Income $1M
Interest Income $1M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $115K
Income Before Tax -$22M
Income Tax Expense $41K
Interest And Debt Expense -
Net Income From Continuing Operations -$22M
Comprehensive Income Net Of Tax -
Ebit -$23M
Ebitda -$23M
Net Income -$22M

Revenue & Profitability

IMMX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $23M
Total Current Assets $20M
Cash And Cash Equivalents At Carrying Value $18M
Cash And Short Term Investments $18M
Inventory -
Current Net Receivables $2M
Total Non Current Assets $2.8M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $542K
Other Non Current Assets -
Total Liabilities $9.7M
Total Current Liabilities $8.7M
Current Accounts Payable $5.4M
Deferred Revenue -
Current Debt -
Short Term Debt $65K
Total Non Current Liabilities $1M
Capital Lease Obligations $1.1M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $1.1M
Other Current Liabilities $3.2M
Other Non Current Liabilities -
Total Shareholder Equity $13M
Treasury Stock -
Retained Earnings -$75M
Common Stock $2.8K
Common Stock Shares Outstanding $28M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$15M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $115K
Capital Expenditures $1.2M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$1.2M
Cashflow From Financing $16M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$22M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$115K
Total Revenue $0
Cost Of Revenue $115K
Costof Goods And Services Sold $115K
Operating Income -$23M
Selling General And Administrative $11M
Research And Development $11M
Operating Expenses $23M
Investment Income Net -
Net Interest Income $1M
Interest Income $1M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $115K
Income Before Tax -$22M
Income Tax Expense $41K
Interest And Debt Expense -
Net Income From Continuing Operations -$22M
Comprehensive Income Net Of Tax -
Ebit -$23M
Ebitda -$23M
Net Income -$22M

IMMX News

IMMX Profile

Immix Biopharma Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, California, focused on developing innovative tissue-specific therapies for oncology and inflammatory diseases. The company boasts a robust pipeline of drug candidates designed to address significant unmet medical needs in the U.S. and Australia. With a strong commitment to advanced research and strategic partnerships, Immix is emerging as a pivotal player in the biopharmaceutical sector, with the potential to deliver transformative therapies that could significantly alter current treatment paradigms.

ATPC
+164.70%
$0.18
LPTX
+368.57%
$2.05
NVDA
-1.55%
$180.93
WOK
-11.57%
$0.16
PAVS
-9.21%
$0.03
VSME
+11.42%
$0.09
PETS
+68.36%
$2.98
RZLT
-87.20%
$1.40
YGMZ
-61.42%
$0.02
PLUG
+4.42%
$2.36
ORCL
-10.83%
$198.85
RIVN
-6.11%
$16.43
ASST
-7.82%
$0.92
VIVK
+14.55%
$0.07
URG
-8.08%
$1.25
KIND
+9.48%
$2.77
NXDR
+9.48%
$2.77
AXDX
-61.36%
$0.03
IVP
-12.52%
$0.05
ONDS
+8.34%
$9.02
IRBT
-4.58%
$5.00
INTC
-3.11%
$39.51
F
+1.64%
$13.63
MIGI
-8.95%
$6.10
KVUE
0.00%
$17.32
TSLA
-1.01%
$446.89
BTTC
+24.28%
$4.12
ADAP
-15.14%
$0.05
DNN
+2.60%
$2.76
AAL
-1.18%
$14.96
AVGO
-1.59%
$406.37
HOOD
-9.05%
$123.38
MARA
-0.67%
$11.84
NFLX
+1.48%
$94.09
TE
-4.55%
$5.87
WBD
-0.13%
$29.49
SOND
-23.45%
$0.12
GOOGL
-2.42%
$312.43
SOFI
-0.07%
$27.07
BMNR
-5.00%
$38.38
RR
+12.77%
$4.68
BTG
0.00%
$4.68
VALE
+2.30%
$13.29
RMBL
+60.50%
$3.21
NIO
+1.98%
$5.13
T
-0.36%
$24.30
LNW
-3.71%
$86.22
RGTI
+2.90%
$26.88
BYND
-4.06%
$1.18
ADD
-25.47%
$0.05
PLTR
-0.19%
$187.54
BAC
+0.88%
$54.56
PFE
+0.07%
$25.80
SRM
+53.27%
$10.30
HL
+12.56%
$19.35
ASBP
+22.50%
$0.10
PLTD
+0.15%
$6.32
AAPL
-0.26%
$278.03
GRAB
0.00%
$5.18
BITF
0.00%
$2.94
HPE
-2.85%
$24.54
RKLB
+10.44%
$63.53
QBTS
+4.40%
$27.98
RIG
-0.46%
$4.28
JBLU
-2.78%
$4.89
AMD
+0.00%
$221.43
BMNU
-10.03%
$10.22
CIFR
+2.16%
$18.88
NGD
+9.19%
$8.55
ACHR
+2.27%
$8.56
AG
+7.13%
$16.81
CDE
+9.45%
$17.48
AMZN
-0.64%
$230.28
SNAP
-3.53%
$7.64
MTSR
-0.35%
$70.50
BBD
+2.71%
$3.41
BTBT
+4.23%
$2.46
NCLH
+6.80%
$20.55
CRWV
-0.88%
$87.38
IREN
+0.04%
$43.94
ABEV
+2.04%
$2.50
FI
+2.38%
$68.16
GOOG
-2.27%
$313.70
NOK
+2.25%
$6.36
MSFT
+1.02%
$483.47
HBAN
+1.99%
$17.91
CCL
+5.93%
$27.84
PCG
-1.65%
$14.83
AFMD
-34.94%
$0.18
UBER
+1.52%
$85.44
SMCI
-2.52%
$34.02
KO
-1.56%
$69.11
WULF
+0.44%
$15.83
LUV
+2.28%
$40.74
SOUN
-1.47%
$12.03
SMR
+4.42%
$21.22
CNQ
-1.72%
$33.14
VZ
+0.75%
$40.22
CHR
-5.72%
$0.04
CLSK
+1.99%
$14.82
ATPC
+164.70%
$0.18
LPTX
+368.57%
$2.05
NVDA
-1.55%
$180.93
WOK
-11.57%
$0.16
PAVS
-9.21%
$0.03
VSME
+11.42%
$0.09
PETS
+68.36%
$2.98
RZLT
-87.20%
$1.40
YGMZ
-61.42%
$0.02
PLUG
+4.42%
$2.36
ORCL
-10.83%
$198.85
RIVN
-6.11%
$16.43
ASST
-7.82%
$0.92
VIVK
+14.55%
$0.07
URG
-8.08%
$1.25
KIND
+9.48%
$2.77
NXDR
+9.48%
$2.77
AXDX
-61.36%
$0.03
IVP
-12.52%
$0.05
ONDS
+8.34%
$9.02
IRBT
-4.58%
$5.00
INTC
-3.11%
$39.51
F
+1.64%
$13.63
MIGI
-8.95%
$6.10
KVUE
0.00%
$17.32
TSLA
-1.01%
$446.89
BTTC
+24.28%
$4.12
ADAP
-15.14%
$0.05
DNN
+2.60%
$2.76
AAL
-1.18%
$14.96
AVGO
-1.59%
$406.37
HOOD
-9.05%
$123.38
MARA
-0.67%
$11.84
NFLX
+1.48%
$94.09
TE
-4.55%
$5.87
WBD
-0.13%
$29.49
SOND
-23.45%
$0.12
GOOGL
-2.42%
$312.43
SOFI
-0.07%
$27.07
BMNR
-5.00%
$38.38
RR
+12.77%
$4.68
BTG
0.00%
$4.68
VALE
+2.30%
$13.29
RMBL
+60.50%
$3.21
NIO
+1.98%
$5.13
T
-0.36%
$24.30
LNW
-3.71%
$86.22
RGTI
+2.90%
$26.88
BYND
-4.06%
$1.18
ADD
-25.47%
$0.05
PLTR
-0.19%
$187.54
BAC
+0.88%
$54.56
PFE
+0.07%
$25.80
SRM
+53.27%
$10.30
HL
+12.56%
$19.35
ASBP
+22.50%
$0.10
PLTD
+0.15%
$6.32
AAPL
-0.26%
$278.03
GRAB
0.00%
$5.18
BITF
0.00%
$2.94
HPE
-2.85%
$24.54
RKLB
+10.44%
$63.53
QBTS
+4.40%
$27.98
RIG
-0.46%
$4.28
JBLU
-2.78%
$4.89
AMD
+0.00%
$221.43
BMNU
-10.03%
$10.22
CIFR
+2.16%
$18.88
NGD
+9.19%
$8.55
ACHR
+2.27%
$8.56
AG
+7.13%
$16.81
CDE
+9.45%
$17.48
AMZN
-0.64%
$230.28
SNAP
-3.53%
$7.64
MTSR
-0.35%
$70.50
BBD
+2.71%
$3.41
BTBT
+4.23%
$2.46
NCLH
+6.80%
$20.55
CRWV
-0.88%
$87.38
IREN
+0.04%
$43.94
ABEV
+2.04%
$2.50
FI
+2.38%
$68.16
GOOG
-2.27%
$313.70
NOK
+2.25%
$6.36
MSFT
+1.02%
$483.47
HBAN
+1.99%
$17.91
CCL
+5.93%
$27.84
PCG
-1.65%
$14.83
AFMD
-34.94%
$0.18
UBER
+1.52%
$85.44
SMCI
-2.52%
$34.02
KO
-1.56%
$69.11
WULF
+0.44%
$15.83
LUV
+2.28%
$40.74
SOUN
-1.47%
$12.03
SMR
+4.42%
$21.22
CNQ
-1.72%
$33.14
VZ
+0.75%
$40.22
CHR
-5.72%
$0.04
CLSK
+1.99%
$14.82
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.